Business
Valeo Pharma Announces Record Revenues and Gross Margins for its Third Quarter 2021
Valeo Pharma Announces Record Revenues and Gross Margins for its Third Quarter 2021.
About this update from Valeo Pharma Inc.
[{"type":"text","content":"\n\n\n\nValeo Pharma Announces Record Revenues and Gross Margins for its Third Quarter 2021\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nValeo Pharma Announces Record Revenues and Gross Margins for its Third Quarter 2021\nCanada NewsWire\nMONTREAL, Sept. 22, 2021\n\n\n\nRecord revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter.Record gross margin of $2.2 million, up 1602% over Q3 2020 and 204% over prior quarter.Record 9 months revenues at $10.2 million, up 94%.Private and public reimbursement coverage expanding for Redesca® New corporate structure completed with full commercial activities ongoing for Redesca®, Enerzair® Breezhaler® and Atectura® Breezhaler® Valeo launches new corporate image, logo and website MONTREAL, Sept. 22, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (\"Valeo\" or the \"Company\"), a Canadian pharmaceutical company, today reported its financial results for the third quarter ended July 31, 2021.\n\n \n \n \n \n \n \n\n \nThird quarter and year to date 2021 Results Highlights:\nRecord revenues of $5.7 million compared to $1.5 million in Q3 2020, up 280% Record gross margin of $2.2 million compared to $0.1 in Q3 2020, up 1602% Net loss of $2.9 million compared to $1.6 in Q3 2020 Adjusted EBITDA loss of $0.8 million compared to $0.7 million in Q3 2020 Record YTD revenues after 9 months of $10.2 million, up 94% over the first 9 months of 2020.\"The Q3 commercial launches of Redesca, Enerzair and Atectura, three products that are transformative for Valeo, contributed to our record third quarter results. Valeo is rapidly evolving into a leading Canadian pharmaceutical company with strong management and an extensive commercial infrastructure. Our innovative products and pipeline point to robust revenue growth for the coming years,\" said Steve Saviuk, CEO. \"Redesca has rapidly become our best selling product while intial healthcare professional interest in Enerzair and Atectura, our two newly launched asthma therapies, has been very strong and supports...